Yanfeng Liu

10PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsProteomics and intermolecular interactions (excl. medical proteomics)Tumour immunologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 14, 2026
ARID2 Loss Reprograms the Kynurenine-AhR Pathway to Restore Antitumor Immunity in CTNNB1-Mutant Hepatocellular Carcinoma.

|Mar 24, 2025
Targeting KMT5C Suppresses Lung Cancer Progression and Enhances the Efficacy of Immunotherapy.

Yunfeng Yuan, Qianyu Li, Guoquan Yan

|Nov 13, 2024
Post-translational toxin modification by lactate controls Staphylococcus aureus virulence.

Yanan Wang, Yanfeng Liu, Guoxiu Xiang

|Jun 22, 2024
Protein O-fucosyltransferase 1 promotes PD-L1 stability to drive immune evasion and directs liver cancer to immunotherapy.

Qianyu Li, Wenyun Guo, Yifei Qian

|Oct 17, 2023
KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.

Wenyun Guo, Songling Li, Yifei Qian

|Aug 09, 2023
Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.

Yu Tong, Fan Wang, Songling Li

Pageof 2

Frequent Collaborators

3 joint publications

Yanan Wang

2 joint publications

Liang Chen

2 joint publications

Wei-Qiang Gao

1 joint publications

Jing Liu